Curaxys obtains financing for the purchase of equipment with the help granted by Innplanta 2012

The Ministry of Economy and Competitiveness resolved favorably, through Innplanta 2012, Subprogram inside the “Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica 2008-2011” developed in Technology Parks, the loan of €543.932 (Project number INP-2012-0110-PCT-010000-ACT3), cofinanced by the European Regional Development Fund (FEDER), “Una manera de hacer Europa”) for the purchase of equipment for R & D for the investigation of processes obtaining generic drugs and biosimilars.

Curaxys SL, founded in 2009 and located in the Technological Park in Cadiz Tecnobahía, again received support from the Ministry of Economy and Competitiveness through the help Innplanta whose main objective is to contribute to creating an environment of collaboration, which allows effective transfer of research results generated in science and technology parks , preferably installed entities in parks, fostering cooperation between the various players in the science , technology and business .

Curaxys has developed and patented three technology platforms themselves , CuraMab ® , GreenMab ® and Xpancell ® to produce biosimilars (monoclonal antibodies ) and for the treatment of diabetic foot through Advanced Therapies . To show its intense research in the biopharmaceutical two years has managed to place in the world ranking tenth in the investigation of generic biologic drugs as stated in a report by Datamonitor ( HC00149 -002 , December 2011 ) .

On the other hand it is noteworthy that, starting this month , Curaxys launches a portfolio of generic medicines as support for research and innovation activity of the company. This portfolio is constantly growing and includes CNS-directed drugs , analgesics , antiplatelet and anticancer , among others , which will expand to 20 molecules so before the end of this year.

Due to the characteristics of Curaxys technology-based company has been supported by the Ministry of Economy and Competitiveness , Ministry of Industry and Commerce and the Government of Andalusia ( Agencia IDEA) and the Centre for Industrial Technological Development ( CDTI ) with the granting of aid as Inncorpora TU and FPGS (2010, 2011, 2012 ) , Torres Quevedo Programme 2010 , Innplanta (2011 , 2012 ) Reindustrialisation (2010, 2011 ) , Regional Incentives , Creating technology-based company , Individual Research Project .

For more information contact:

Head of Communication and Marketing: Paula Esteban del Rio

Mobile: +34  638 438 509

Email: pesteban@curaxys.com

More on Curaxys
We focus on the research, production and commercialization of recombinant proteins added value through the utilization of CuraMab® with specific human cell lines
Our expression system allows us to reach of recombinant protein levels that are clearly above those currently available.
We developed a downstream technological platform on the basis of our own laboratory data.

More articles

  • Curaxys obtains financing for the purchase of equipment with the help granted by Innplanta 2012
  • Curaxys hires five more technologists.
  • One of the largest biopharmaceutical projects in Europe to be started at Tecnobahía.
  • Innovaxis, a novel company for “custom medicine”
  • Strategic Alliance for cancer disease
  • UCA and Curaxys create a Cathedra in biopharmaceuticals in order to research biosimilar proteins
  • Curaxys is ranked among the world top ten companies in the research of biologic generic medicines

  • Copyright 2012 Curaxys. All Rights Reserved
    Legal Advice